Fully human antibodies, developed using human genes, are advancing antibody-based therapeutics. These antibodies reduce immunogenicity, improving patient safety and tolerance. Traditional methods, like humanized mice, require genetic modifications to produce human antibodies, often increasing complexity and cost.
The collaboration between Biointron and Cyagen addresses these challenges with a next-generation platform. By combining Biointron's AbDrop™ technology and Cyagen's HUGO-Ab™ mice, researchers can discover fully human antibodies faster and at a lower cost. This platform accelerates timelines, reduces expenses, and delivers safer and more effective antibody candidates.
Key Advantages of the Biointron and Cyagen Platform
1. Faster Results
The platform significantly reduces timelines by eliminating the humanization process. Fully human antibodies can be identified within three months. This rapid turnaround is critical for biopharmaceutical companies aiming to bring therapies to market quickly.
2. Enhanced Accuracy and Diversity
Access to a diverse pool of high-affinity and highly specific antibodies ensures optimal targeting for therapeutic applications. The platform's precision reduces the risk of off-target effects, improving drug efficacy and safety.
3. Cost-Effectiveness
By streamlining the discovery process and leveraging cutting-edge technologies, the platform minimizes development costs.
4. Clear Intellectual Property (IP) and Royalty-Free Structure
A straightforward IP framework ensures smooth licensing and development processes, removing potential legal hurdles associated with patent disputes.
Our High-throughput Fully Human Antibody Discovery Platform integrates Cyagen’s HUGO-Ab™ mice with Biointron’s AbDrop™ microdroplet-based single B cell screening. This powerful combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months. Learn more about the service here.
